Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus M Fischer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2012
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cellsWan-Ching Yen, Marcus M Fischer, Mark Hynes, et al.
Scientific Reports|November 12, 2017
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutationsMarcus M Fischer, V Pete Yeung, Fiore Cattaruzza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequencyWan-Ching Yen, Marcus M Fischer, Fumiko Axelrod, et al.
Science Advances|July 11, 2017
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell deathMarcus M Fischer, Belinda Cancilla, V Pete Yeung, et al.
Cancer Research|January 1, 2016
Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer TypesCecile Chartier, Janak Raval, Fumiko Axelrod, et al.
Nature|May 11, 2017
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancerJing Shan Lim, Alvaro Ibaseta, Marcus M Fischer, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2012
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cellsWan-Ching Yen, Marcus M Fischer, Mark Hynes, et al.
Scientific Reports|November 12, 2017
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutationsMarcus M Fischer, V Pete Yeung, Fiore Cattaruzza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequencyWan-Ching Yen, Marcus M Fischer, Fumiko Axelrod, et al.
Science Advances|July 11, 2017
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell deathMarcus M Fischer, Belinda Cancilla, V Pete Yeung, et al.
Cancer Research|January 1, 2016
Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer TypesCecile Chartier, Janak Raval, Fumiko Axelrod, et al.
Nature|May 11, 2017
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancerJing Shan Lim, Alvaro Ibaseta, Marcus M Fischer, et al.
Pageof 1